Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.97
-1.60 (-5.60%)
At close: Feb 27, 2026, 4:00 PM EST
26.70
-0.27 (-1.00%)
After-hours: Feb 27, 2026, 6:54 PM EST
Arcutis Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 372.07 | 166.54 | 29.19 | 3.69 | - | |
| Other Revenue | 4 | 30 | 30.42 | - | - | |
| Revenue | 376.07 | 196.54 | 59.61 | 3.69 | - | |
| Revenue Growth (YoY) | 91.34% | 229.73% | 1517.09% | - | - | |
| Cost of Revenue | 36.7 | 19.13 | 4.99 | 0.75 | - | |
| Gross Profit | 339.38 | 177.41 | 54.62 | 2.93 | - | |
| Selling, General & Admin | 274.55 | 229.39 | 185.15 | 122.12 | 60.97 | |
| Research & Development | 77.05 | 76.42 | 110.58 | 182.44 | 145.56 | |
| Operating Expenses | 351.6 | 305.81 | 295.72 | 304.56 | 206.53 | |
| Operating Income | -12.23 | -128.4 | -241.1 | -301.63 | -206.53 | |
| Interest Expense | -12.08 | -27.17 | -29.71 | -15.65 | - | |
| Interest & Investment Income | 8.9 | 16.13 | 12.52 | 5.82 | 0.17 | |
| Other Non Operating Income (Expenses) | 0.44 | 0.05 | -0.73 | - | - | |
| Pretax Income | -14.97 | -139.39 | -259.03 | -311.46 | -206.36 | |
| Income Tax Expense | 1.17 | 0.65 | 3.11 | - | - | |
| Net Income | -16.14 | -140.04 | -262.14 | -311.46 | -206.36 | |
| Net Income to Common | -16.14 | -140.04 | -262.14 | -311.46 | -206.36 | |
| Shares Outstanding (Basic) | 127 | 121 | 69 | 55 | 49 | |
| Shares Outstanding (Diluted) | 127 | 121 | 69 | 55 | 49 | |
| Shares Change (YoY) | 5.19% | 74.53% | 25.94% | 11.39% | 38.52% | |
| EPS (Basic) | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 | |
| EPS (Diluted) | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 | |
| Free Cash Flow | -6.31 | -112.3 | -247.49 | -258.05 | -175.62 | |
| Free Cash Flow Per Share | -0.05 | -0.93 | -3.57 | -4.69 | -3.56 | |
| Gross Margin | 90.24% | 90.27% | 91.63% | 79.54% | - | |
| Operating Margin | -3.25% | -65.33% | -404.49% | -8183.04% | - | |
| Profit Margin | -4.29% | -71.25% | -439.79% | -8449.76% | - | |
| Free Cash Flow Margin | -1.68% | -57.14% | -415.20% | -7000.76% | - | |
| EBITDA | -7.56 | -126.44 | -240.35 | -300.69 | -206.08 | |
| EBITDA Margin | -2.01% | -64.33% | - | - | - | |
| D&A For EBITDA | 4.67 | 1.96 | 0.75 | 0.93 | 0.45 | |
| EBIT | -12.23 | -128.4 | -241.1 | -301.63 | -206.53 | |
| EBIT Margin | -3.25% | -65.33% | - | - | - | |
| Revenue as Reported | 376.07 | 196.54 | 59.61 | 3.69 | - | |
| Advertising Expenses | 25.3 | 6.9 | 11.2 | 1.5 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.